These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10711852)

  • 21. Patient selection for oral chemotherapy.
    Sharma S
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):33-5. PubMed ID: 11219975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents.
    Bedell CH
    Clin J Oncol Nurs; 2003; 7(6 Suppl):5-9. PubMed ID: 14705494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NCCN Task Force Report: Oral chemotherapy.
    Weingart SN; Brown E; Bach PB; Eng K; Johnson SA; Kuzel TM; Langbaum TS; Leedy RD; Muller RJ; Newcomer LN; O'Brien S; Reinke D; Rubino M; Saltz L; Walters RS
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 3():S1-14. PubMed ID: 18377852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral cancer treatment: developments in chemotherapy and beyond.
    O'Neill VJ; Twelves CJ
    Br J Cancer; 2002 Oct; 87(9):933-7. PubMed ID: 12434279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using tools and technology to promote education and adherence to oral agents for cancer.
    Burhenn PS; Smudde J
    Clin J Oncol Nurs; 2015 Jun; 19(3 Suppl):53-9. PubMed ID: 26030395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic education of patients taking oral chemotherapy at home].
    Dhellemmes A; Delmas S; Sordes F
    Soins; 2018 Dec; 63(831):21-25. PubMed ID: 30551748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient adherence with oral oncolytic therapies.
    Vioral A; Leslie M; Best R; Somerville D
    Semin Oncol Nurs; 2014 Aug; 30(3):190-9. PubMed ID: 25085031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral chemotherapy safety practices at US cancer centres: questionnaire survey.
    Weingart SN; Flug J; Brouillard D; Morway L; Partridge A; Bartel S; Shulman LN; Connor M
    BMJ; 2007 Feb; 334(7590):407. PubMed ID: 17223629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in oral chemotherapy options for gastric carcinoma.
    Ajani JA; Takiuchi H
    Drugs; 1999; 58 Suppl 3():85-90. PubMed ID: 10711846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
    André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
    Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.
    Moes J; Koolen S; Huitema A; Schellens J; Beijnen J; Nuijen B
    Eur J Pharm Biopharm; 2013 Jan; 83(1):87-94. PubMed ID: 23085332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metronomics chemotherapy: time for computational decision support.
    Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral chemotherapy practices at Ontario cancer centres.
    Ahmad N; Simanovski V; Hertz S; Klaric G; Kaizer L; Krzyzanowska MK
    J Oncol Pharm Pract; 2015 Aug; 21(4):249-57. PubMed ID: 24714129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
    Terwogt JM; Schellens JH; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1999 Apr; 25(2):83-101. PubMed ID: 10395834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
    Veltkamp SA; Rosing H; Huitema AD; Fetell MR; Nol A; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):635-42. PubMed ID: 17205304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetic aspects of oral administration of etoposide].
    Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
    Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adherence to oral antineoplastic therapy].
    Olivera-Fernandez R; Fernandez-Ribeiro F; Piñeiro-Corrales G; Crespo-Diz C
    Farm Hosp; 2014 Nov; 38(6):475-81. PubMed ID: 25542658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study.
    Spoelstra SL; Given BA; Given CW; Grant M; Sikorskii A; You M; Decker V
    Cancer Nurs; 2013; 36(1):18-28. PubMed ID: 23235499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient education: the cornerstone of successful oral chemotherapy treatment.
    Hartigan K
    Clin J Oncol Nurs; 2003; 7(6 Suppl):21-4. PubMed ID: 14705496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.